Solutions For Healthcare Providers

iLink Corneal
Cross-Linking

iLink is the first and only FDA-approved corneal cross-linking procedure that slows or halts the progression of keratoconus and helps preserve vision.

Watch this video for unique patient and doctor perspectives about progressive keratoconus and learn how the condition is treated with iLink corneal cross-linking.

Contact Representative

Explore The Results of Our Clinical Study Data

In clinical studies, cross-linking–treated eyes showed increasing improvement in Kmax from month 3 through month 12, while in untreated, sham eyes, Kmax demonstrated steepening.3

View Clinical Data

If it’s not iLink, it’s not FDA approved

When it comes to referring patients with progressive keratoconus for treatment, iLink is the only FDA-approved corneal cross-linking procedure.

Learn More

Explore Patient Resources for Keratoconus
Treatment Options

View Patient Website

Reimbursement Support

Tailor-Made
Market
Access Solutions

Looking for reimbursement info? The iPath360 program provides strategic and trustworthy market access solutions for all Glaukos procedures and products in glaucoma, corneal health, and retinal disease care.

Reimbursement Info

Resources for Healthcare Professionals

Learn More About iLink from the Experts

Order print versions of our practice marketing materials, including educational resources on keratoconus and FDA-approved cross-linking. You can also download digital versions of many of our educational resources.

View Resources

Contact Us Today
to Integrate the iLink
Procedure Into Your
Practice

Explore additional information about iLink™ in our digital brochure and learn how the procedure is transforming the standard of care for progressive keratoconus.

Request
More Info

Glaukos will use the information you provide on this form to be in touch with you.*
This field is for validation purposes and should be left unchanged.

References

  • Pramanik S, Musch DC, Sutphin JE, Farjo AA. Extended long-term outcomes of penetrating keratoplasty for keratoconus. Ophthalmology. 2006;113(9):1633-1638.
  • Maharana PK, Agarwal K, Jhanji V, Vajpayee RB. Deep anterior lamellar keratoplasty for keratoconus: a review. Eye Contact Lens. 2014;40(6):382-389.
  • Photrexa [package insert]. Waltham, MA: Glaukos, Inc. 2016.

Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and the KXL® System, the iLink™ corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*1

[Photrexa IFU/p1/col1/para3/lines1-4]

Indications

Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

Important Safety Information

Corneal collagen cross-linking should not be performed on pregnant women.

Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all the side effects of the corneal collagen cross-linking treatment. For more information, go www.livingwithkeratoconus.com to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

Reference

1. Photrexa Prescribing Information. Waltham, MA: Glaukos, Inc. 2018